

Product Data Sheet

WM-3835

Molecular Weight:

 Cat. No.:
 HY-134901

 CAS No.:
 2229025-70-9

 Molecular Formula:
 $C_{20}H_{17}FN_2O_4S$

Target: Histone Acetyltransferase; Apoptosis

400.42

Pathway: Epigenetics; Apoptosis
Storage: 4°C, protect from light

* In solvent: -80°C, 2 years; -20°C, 1 year (protect from light)

SOLVENT & SOLUBILITY

In Vitro

DMSO: 250 mg/mL (624.34 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	2.4974 mL	12.4869 mL	24.9738 mL
	5 mM	0.4995 mL	2.4974 mL	4.9948 mL
	10 mM	0.2497 mL	1.2487 mL	2.4974 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- 1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: \geq 2.08 mg/mL (5.19 mM); Clear solution
- 2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE- β -CD in saline) Solubility: \ge 2.08 mg/mL (5.19 mM); Clear solution
- 3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.08 mg/mL (5.19 mM); Clear solution

BIOLOGICAL ACTIVITY

Description	WM-3835 is a potent and high-specific HBO1 (KAT7 or MYST2) inhibitor and binds directly to the acetyl-CoA binding site of HBO1 33. WM-3835 activates apoptosis while inhibits osteosarcoma (OS) cell proliferation, migration and invasion. WM-3835 has antitumor activity and potently inhibits pOS-1 xenograft growth in mice ^[1] .
IC ₅₀ & Target	HBO1
In Vitro	WM-3835 (1-25 uM; 24-96 hours) inhibits pOS-1 cell viability in a concentration-dependent manner $^{[1]}$. ?WM-3835 (5 uM; 72 h) activates cell apoptosis and significantly increases TUNEL-positive nuclei in pOS-1 cells $^{[1]}$. ?WM-3835 (5 µM; 24 hours) downregulates MYLK-HOXA9 mRNA expression in pOS-1 cells $^{[1]}$.

?WM-3835 (1-25 uM) suppresses H4K12ac-H3K14ac in a dose-dependent manner. WM-3835 does not alter the expressions of HBO1 protein and total H3, H4 histones $^{[1]}$.

?WM-3835 (5 μ M) fails to induce apoptosis and reduction of viability in HBO1-KO pOS-1 cells, koHBO1-1 and koHBO1-2, HBO1-low human osteoblasts [1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:	Primary human OS (pOS-1) cells	
Concentration:	1, 5, 10, 25 uM	
Incubation Time:	24, 48, 72, 96 hours	
Result:	Inhibited pOS-1 cell viability in a concentration-dependent manner. Exerted a significant anti-survival activity at least 48 h, displaying a time-dependent manner.	
Apoptosis Analysis ^[1]		
Cell Line:	pOS-1 cells	
Concentration:	5 uM	
Incubation Time:	72 hours	
Result:	Activated cell apoptosis and significantly increases TUNEL-positive nuclei.	
RT-PCR ^[1]		
Cell Line:	pOS-1 cells	
Concentration:	5 uM	
Incubation Time:	24 hours	
Result:	Downregulated MYLK-HOXA9 mRNA expression.	

In Vivo

WM-3835 (10 mg/kg/day; ip; for 21 days) potently inhibits pOS-1 xenograft growth in SCID mice^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	SCID mice (18-19 g, female) with pOS1 cells ^[1]
Dosage:	10 mg/kg
Administration:	IP; daily; for 21 days
Result:	Potently inhibited pOS-1 xenograft growth.

CUSTOMER VALIDATION

• Cell Death Dis. 2023 Aug 4;14(8):498.

See more customer validations on www.MedChemExpress.com

EFERENCES		
]. Yan-Yang Gao, et al. The histone acetyltransferase HBO1 functions as a novel oncogenic gene in osteosarcoma. Theranostics. 2021 Mar 4;11(10):4599-4615.		
	Caution: Product has not been fully validated for medical applications. For research use only.	
	Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com	
	Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA	

Page 3 of 3 www.MedChemExpress.com